| Literature DB >> 32848198 |
Elzbieta Masiewicz1,2, George P Ashcroft3, David Boddie3, Sinclair R Dundas4, Danuta Kruk1, Lionel M Broche5.
Abstract
This work explores what Fast Field-Cycling Nuclear Magnetic Resonance (FFC-NMR) relaxometry brings for the study of sarcoma to guide future in vivo analyses of patients. We present the results of an ex vivo pilot study involving 10 cases of biopsy-proven sarcoma and we propose a quantitative method to analyse 1H NMR relaxation dispersion profiles based on a model-free approach describing the main dynamical processes in the tissues and assessing the amplitude of the Quadrupole Relaxation Enhancement effects due to 14N. This approach showed five distinct groups of dispersion profiles indicating five discrete categories of sarcoma, with differences attributable to microstructure and rigidity. Data from tissues surrounding sarcomas indicated very significant variations with the proximity to tumour, which may be attributed to varying water content but also to tissue remodelling processes due to the sarcoma. This pilot study illustrates the potential of FFC relaxometry for the detection and characterisation of sarcoma.Entities:
Mesh:
Year: 2020 PMID: 32848198 PMCID: PMC7449965 DOI: 10.1038/s41598-020-71067-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 11H spin–lattice relaxation dispersion profiles for all the tissue samples, before the scaling procedure. Fatty tissues (in red) show a marked two-segment shape in log–log plots, which clearly differs from all other samples except for oedematous fatty tissues in patients a and b, which appeared closer to tumour profiles. Dispersion profiles from muscle (in green) and tumours (in blue), on the other hand, exhibit similar shapes with quadrupolar peaks around 2.5 MHz and large dispersions below 100 kHz (2.3 mT). Measurement errors were typically between 1 and 4% of R1.
Parameters obtained from histopathology examination for the individual tumour samples.
| Patient code | Number of tumour samples | Tumour type | Histological gradea | pT stageb | Anatomical site | Age | Gender | MC | I |
|---|---|---|---|---|---|---|---|---|---|
| a | 2 | Dedifferentiated liposarcoma | 3 | 3 | Right thigh | 68 | Female | N | N |
| b | 2, with 1 necrotic | Dedifferentiated liposarcomac | 3 | 1 | Left proximal leg | 78 | Female | Y | N |
| c | 2 | Leiomyosarcoma | 2 | 2 | Right groin | 49 | Female | N | N |
| d | 2 | Undifferentiated pleomorphic sarcoma | 3 | 4 | Left leg | 54 | Male | Y | Ye |
| e | 2 | Ewing sarcomad | 3 | 3 | Cranio-occipital | 46 | Male | N | N |
| f | 2 | Undifferentiated pleomorphic sarcoma | 3 | 3 | Deltoid muscle | 59 | Male | Y | Y |
| g | 2, with 1 necrotic | Undifferentiated pleomorphic sarcoma | 3 | 4 | Left proximal thigh | 80 | Male | N | Yf |
| h | 1 | Chondrosarcoma | 2 | 2 | Sternum | 43 | Male | N | N |
| i | 1 | Myxofibrosarcoma | 2 | 1 | Posterior shoulder | 61 | Female | Y | Y |
| j | 2 (1 necrotic) | Giant cell-rich pleomorphic sarcoma | 2 | 2 | Pelvis | 79 | Female | N | Yf |
aTrojani grade for soft tissue tumours. Ewing sarcoma high grade 3 by definition.
bUICC TNM8.
cIncluding heterologous rhabdomyosarcomatous differentiation.
dCD99/ EWSR1 translocation positive.
ePeri-tumoural muscle was inflamed.
fHaemosiderin deposition.
Figure 2Comparison of R1 relaxation dispersion profiles for the resections presenting both sarcoma and muscle tissue samples. Each graph presents the raw (markers) and the scaled data (solid lines) to provide an overview of the scaling factors found in each sample (value shown in the legends). In patients a, d, e and h, significant differences appeared at low frequencies after applying the scaling procedure described in the methods. These were particularly large in patients d and e.
Figure 31H spin–lattice relaxation dispersion profiles for (a) sarcoma and (b) muscle tissues, grouped according to the description in the text. Red lines stand for the theoretical fits.
Parameters obtained from the analysis of the groups of 1H relaxation dispersion profiles for muscle and pathological tissues.
| Fit parameter | Muscles | Sarcomas | ||||||
|---|---|---|---|---|---|---|---|---|
| Group I | Group II | Group III | Group A | Group B | Group C | Group D | Group E | |
| 82.1 (17) | 214 (29) | 216 (22) | 76.6 (25) | 81.7 (19) | 179 (23) | 240 (32) | 281 (35) | |
| 9.72 (2.4) | 23.3 (3.5) | 23.4 (3.2) | 6.5 (2.1) | 9.3 (2.3) | 22.3 (3.8) | 29.8 (4.9) | 35.4 (5.1) | |
| 5.21 (0.58) | 5.36 (0.29) | 6.03 (0.35) | 4.46 (0.74) | 4.90 (0.60) | 5.27 (0.22) | 5.35 (0.24) | 5.88 (0.39) | |
| 530 (64) | 640 (74) | 879 (70) | 516 (87) | 524 (69) | 527 (54) | 610 (73) | 899 (102) | |
| 38.6 (7.1) | 38.9 (5.6) | 39.8 (4.1) | 39.6 (6.9) | 41.0 (7.3) | 37.3 (6.4) | 41.2 (6.8) | 41.4 (5.1) | |
| 3.12 (0.32) | 3.03 (0.24) | 3.03 (0.21) | 2.72 (0.18) | 2.71 (0.19) | 2.23 (0.16) | 2.18 (0.17) | 2.38 (0.09) | |
| 1.02 (0.26) | 1.04 (0.23) | 1.07 (0.18) | 0.98 (0.22) | 1.00 (0.21) | 1.00 (0.18) | 1.03 (0.15) | 1.02 (0.20) | |
| 0.42 | 0.40 | 0.41 | 0.42 | 0.40 | 0.41 | 0.41 | 0.40 | |
| 3.25 | 3.29 | 3.30 | 3.26 | 3.26 | 3.29 | 3.29 | 3.30 | |
| Θ (°) | 77 (22) | 77 (25) | 74 (17) | 77 (20) | 78 (20) | 80 (25) | 78 (18) | 75 (21) |
| Φ (°) | 53 (6) | 57 (6) | 57 (4) | 48 (5) | 53 (5) | 52 (4) | 54 (3) | 53 (4) |
| 3.27 (0.16) | 3.30 (0.14) | 3.26 (0.10) | 3.57 (0.16) | 3.48 (0.13) | 3.43 (0.12) | 3.26 (0.09) | 3.49 (0.14) | |